Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients

Citation
N. Guvener et O. Gedik, Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients, ACT DIABETO, 36(1-2), 1999, pp. 93-97
Citations number
22
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
ACTA DIABETOLOGICA
ISSN journal
09405429 → ACNP
Volume
36
Issue
1-2
Year of publication
1999
Pages
93 - 97
Database
ISI
SICI code
0940-5429(199906)36:1-2<93:EOCOIA>2.0.ZU;2-Z
Abstract
In this prospective study we aimed to compare insulin plus acarbose with in sulin plus gliclazide with respect to their effect on insulin requirement, lipid profiles and body mass index (BMI) while achieving good glycemic cont rol. Forty patients with type 2 diabetes mellitus who were on conventional insulin therapy (subcutaneous insulin therapy consisting of regular and NPH insulin, two times a day) were included in the study. They were randomized to double blind treatment with insulin in combination with gliclazide or a carbose for 6 months. For both groups, acceptable glycemic control was achi eved at the end of study period. The mean HbA(1c) levels decreased from 8.3 2+/-0.26 to 7.13+/-0.18% in acarbose group and 8.6+/-0.15 to 7.48+/-0.21% i n the gliclazide group. The difference between groups was not significant ( P 0.29). In the acarbose group, total cholesterol and LDL concentration dec reased significantly while other parameters did not change. In the gliclazi de group, HDL levels decreased significantly from 46.6+/-2.48 mg/dl to 41.3 +/-2.09 mg/dl (P 0.001) BMI increased significantly from 27.60+/-1.21 kg/m( 2) to 28.69+/-1.26 kg/m(2). (P 0.003) Total daily insulin dose was not chan ged in the acarbose group significantly, but increased from 42.6+/-2.73 to 49.27+/-3.58 U/day, which was significant in gliclazide group of (P 0.016). In the acarbose group, there were no significant differences between respo nders and nonresponders with respect to fasting and stimulated C-peptide, H bA(1c) levels and baseline BMI values. But in the gliciazide group, baselin e BMI values were significantly higher in the nonresponding group compared to responders (P 0.02). In conclusion, combination of insulin with acarbose can be a good alternative for type 2 diabetic patients on insulin therapy; seems more beneficial than combination with gliclazide; may have advantage of achieving good glycemic control without increasing insulin dose and BMI ; also may have the advantage of providing a decrease in LDL level, which a re all important to prevent atherosclerosis.